✦ LIBER ✦

Development of cardiovascular drugs: The U.S. regulatory milieu from the perspective of a participating nonregulator

✍ Scribed by Jeffrey S. Borer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current regulatory perspectives on genot

✍ Kuei-Meng Wu; Jinhui Dou; Hanan Ghantous; Shaw Chen; Anita Bigger; Debra Birnkra 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Developing new drugs for the treatment o

✍ Leonard V. Sacks; Rachel E. Behrman 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Regulatory Federalism in the Age of Broa

✍ Michael J. Santorelli 📂 Article 📅 2010 🏛 Walter de Gruyter GmbH & Co. KG 🌐 English ⚖ 277 KB

Regulatory issues facing the development

✍ Boam, Ashley B 📂 Article 📅 2006 🏛 Expert Reviews 🌐 English ⚖ 56 KB

On the Development of Antifungal Agents:

✍ Wu, T. C. 📂 Article 📅 1994 🏛 University of Chicago Press 🌐 English ⚖ 435 KB

A regulatory perspective on the developm

✍ Michael B. Havert 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 112 KB